![Open Access](/resources/images/iconopenaccess.png)
Interleukin‑15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model
- Authors:
- Published online on: August 14, 2018 https://doi.org/10.3892/ol.2018.9303
- Pages: 4839-4846
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Gastric cancer is the fourth most common cause of cancer-associated mortality worldwide (1). The major causes of mortality are due to local recurrence and distant metastasis (2). Liver metastasis can be found in 5–9% of patients with gastric cancer (3–5). Liver metastasis from gastric cancer (LMGC) has a poor prognosis and there are no effective treatment modalities (6). The present treatment of LMGC includes surgical resection, radiofrequency ablation, hepatic arterial infusion, systemic chemotherapy and targeted therapy (7). However, current treatments are ineffective and the prognosis is poor. Therefore, studies on LMGC remain an important issue.
Interleukin (IL)-15 was co-discovered by two different studies in 1994 and characterized as a T cell growth factor (8,9). Mature human IL-15 is a 14–15 kDa glycoprotein and a member of the four α-helix bundle family of cytokines (10). IL-15 binds to the IL-15-specific high affinity binding protein IL-15Rα and signals through a β chain and a γ chain signaling complex, leading to the recruitment of Janus kinase (JAK) JAK1 by the β chain and activation of JAK3 that is constitutively associated with the γ chain (11). IL-15 performs important roles in immune response, such as stimulating the proliferation of activated T cells (9), B cells (12) and NK cells (13), and shares two receptor subunits with IL-2 (14,15). IL-15 has innate antitumor activity independent of NK and CD8 T cells (16). The direct administration of IL-15 has shown antitumor effects in several preclinical studies of IL-15 immunotherapy in murine tumor models (17,18). Thus far, there have been seven clinical trials initiated to explore anticancer vaccination or immunotherapy with IL-15 (19).
According to recent advances, IL-15 is a promising cytokine for cancer immunotherapy, however the association between IL-15 and LMGC remains unknown. Therefore, the present study used a LMGC mouse model to investigate the role of IL-15 in liver metastasis. Using different doses for treatment, the role of IL-15 in LMGC was investigated.
Materials and methods
Cell line
The gastric cancer MKN45 cell line and YAC-1, a mouse lymphoma cell line sensitive to NK cells, were obtained from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2, and maintained in RPMI-1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all supplied by Invitrogen; Thermo Fisher Scientific, Inc.). Stable green fluorescent protein (GFP)-expressing MKN45 cells (MKN45-GFP) were maintained in the same culture as the MKN45 cells.
Mice
Female BALB/c nu/nu mice (n=54) and BALB/c mice (n=18), 4–6-week-old and 15–20 g, were purchased from Chinese Academy of Sciences. All mice were maintained under specific pathogen-free conditions in the Animal Facility of Fudan University (Shanghai, China). Mice were fed a standard laboratory chow, given water as required and subjected to an equal 12-h light/dark cycle in accordance with institutional guidelines. These experiments were approved by the Shanghai Medical Experimental Animal Care Commission.
Liver metastasis model and treatment procedure
A total of 1×106 (0.2 ml) MKN45-GFP cells were re-suspended in sterile PBS and injected into the spleen parenchyma of all mice following anesthesia using 1% pentobarbital sodium (50 mg/kg). The spleen was removed 5 min following tumor injection to prevent spleen tumor formation, so that metastatic lesions developed only in the liver.
All BALB/c nu/nu mice (n=36) were randomly assigned to receive the following treatments: Low dose group (n=12), 0.2 µg rmIL-15 in 0.1 ml saline; high dose group (n=12), 2.5 µg rmIL-15 in 0.1 ml saline; control group (same volume of PBS, 0.1 ml, n=12). All the mice were treated 5 times a week for 3 weeks. On day 28, 6 mice from each group were sacrificed, their livers were harvested, the number of liver metastases nodules was counted and liver weight was measured. The rest of the mice (3 groups, n=6/group) were monitored for survival according to the different therapies (0.2 µg rmIL-15, 2.5 µg rmIL-15 or PBS).
Assessment of liver tissue
The livers were excised and fixed with 10% buffered formalin for 24 h at 4°C and were paraffin-embedded. Stable GFP-expressing MKN45-GFP cells were injected into the spleen parenchyma Tissues were cut into 5 µm thick serial sections for fluorescent imaging. The number of liver metastatic nodules in each tissue section were evaluated by fluorescence microscopy (Olympus Corporation, Tokyo, Japan).
ELISA of cytokines
Blood samples (1 ml, n=6/group) were obtained from the tail vein of mice on day 12. Blood was centrifuged at 1,000 × g for 15 min at room temperature. Subsequently, the serum was extracted and the extracted serum was stored at −80°C. The serum IL-15 and interferon (IFN)-γ concentrations were measured by ELISA with the use of Quantikine ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA), and the ELISA was performed as indicated in the manufacturer's protocol. Quantifications were conducted in triplicate.
Flow cytometric analysis
Selective NK depletion was confirmed with a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) on day 21. Blocking was performed using FcR Blocking Reagent mouse (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) at 4°C for 30 min. The mouse splenocytes were incubated with saturating amounts (1 µg/106 cells) of phycoerythrin conjugated anti-mouse cluster of differentiation (CD) 49b monoclonal antibody (mAb; 1:100; cat. no., 553858; BD Biosciences) and fluorescein isothiocyanate-conjugated anti-mouse CD3 mAb (1:100; cat. no. 555274; BD Biosciences) for 30 min at 4°C. Following incubation, cells were washed once in PBS (400 × g for 15 min at 4°C) and analyzed for fluorescence intensity using the FACS Calibur cytometer Data were processed using FlowJo software version 7.6 (BD Biosciences).
Cytotoxicity assay
Effector cells from each of the treatment groups were cultured with 1×104 MKN45 target cells/well in triplicate at varying effector to target cell ratios, and incubated at 37°C for 4 h. Cytotoxic activity was measured by lactate dehydrogenase release. The percentage cytotoxicity was calculated as 100× [(experimental release)-(effector spontaneous release)-(target spontaneous release)]/[(target maximum release)-(target spontaneous release)].
Statistical analysis
All statistical analyses were performed with SPSS 19.0 for Windows (IBM Corp., Armonk, NY, USA). Data are presented as the mean ± standard deviation. The statistical significance of differences in survival of the mice in different groups was determined by the log-rank test. Statistical differences in the data were evaluated by a Student's t-test or one-way analysis of variance as appropriate, the post-hoc test used was the least significant difference test. P<0.05 was considered to indicate a statistically significant difference.
Results
IL-15 treatment leads to decreased liver metastasis
Nude mice were treated with gastric carcinoma MKN45-GFP cells into the spleen parenchyma (Fig. 1). rmIL-15 was intraperitoneally administered 5 times a week for 3 weeks at 2.5 µg (high dose) or 0.2 µg (low dose) per injection. PBS was used as the control group. The development of liver metastases was assessed in detection of liver metastasis by fluorescent microscopy (Fig. 2). The tumor appearance, liver weight and number of liver metastasis nodules were monitored. rmIL-15 was found to inhibit metastatic dissemination of MKN45-GFP cells: 66.7% (4/6) and 83.3% (5/6) of mice administered high or low dose rmIL-15 developed liver metastases, respectively, in contrast to 100% (6/6) among PBS-treated mice (P>0.05; Fig. 3A). Liver weight was not significantly increased in mice treated with rmIL-15 compared with PBS-treated mice (P>0.05; Fig. 3B). In addition, high dose rmIL-15 also led to a significant reduction in the number of liver metastasis nodules compared with low dose treatment (P<0.05) and high dose rmIL-15 led to a decrease in the number of liver metastasis nodules compared with that observed in the PBS-treated group (P<0.05) (Fig. 3C).
IL-15 treatment increases the survival rate of nude mice
In the survival assay, mice were monitored daily until mortality occurred. The Kaplan-Meier survival curves showed that the probability of survival was significantly higher for mice treated with the high dose rmIL-15 therapy (P<0.01 vs. low dose; P<0.005 vs. control; Fig. 3D). Mice treated with PBS survived a median of 32 days (range, 21–46 days). Animals treated with low dose rmIL-15 did not show a survival advantage over animals treated with PBS (median survival, 44 days; range, 28–57 days; P>0.05). Mice receiving high dose rmIL-15 (median survival, 59 days; range, 43–88 days) demonstrated a significant prolongation of survival when compared with the PBS-treated group (Fig. 3E). Lifespan rate was calculated as the ratio of treated/control group. High dose rmIL-15 therapy led to an increased life-span rate of (109%), whereas low dose rmIL-15 improved by only (36%) (Fig. 3F).
IL-15 treatment increases the concentration of IFN-γ in the bloodstream
Blood samples were obtained from the tail vein of mice on day 12. IL-15 and IFN-γ secretion was measured. Mice treated with rmIL-15 demonstrated an increased IFN-γ secretion compared with the PBS control group in nude mice as well as the Balb/c mouse model (P<0.05; Fig. 4).
IL-15 induces NK cell proliferation and lytic activity
The target cells used were YAC-1 and MKN45 in NK cell assays The studies showed that treatment with either high dose mIL-15 or low dose mIL-15 had greater therapeutic efficacy. NK cells are involved in the antitumor action mediated by mIL-15 in nude mice or Balb/c mice model. It was revealed that mIL-15 treatment induced NK cell proliferation (Fig. 5) and increased the cytotoxic activity of NK cells (Fig. 6) in nude mice and Balb/c mice.
Discussion
In 1889, Paget (20) found that the organ distribution of metastases is not a matter of chance and first noted that metastasis from specific tumor types grew in select secondary organ sites. Paget suggested that metastases develop only when the seed (certain tumor cells with metastatic ability) and the soil (organs providing growth advantage to the seeds) are compatible (20). Paget's seed and soil hypothesis stated that cancer metastasis requires permissive interactions between tumor cells and secondary organ microenvironments. IL-15 is a pleiotropic cytokine sharing structural homology and receptor components with IL-2 (21,22). IL-2 has been approved by the Food and Drug Administration for use in the treatment of patients with metastatic renal cell carcinoma and malignant melanoma (23,24). However, its toxicity at high doses as well as its ability to promote activation-induced cell death and expansion of T regulatory cells had limited its contemplated use in cancer treatment (25). In the past, the antitumor effect of IL-15 has been widely reported (26–28), and it has been recognized as a more promising cytokine than IL-2, with the potential for application in tumor therapy, since IL-15 is more potent than IL-2 in tumor therapy with greater therapeutic index (29).
In recent years, several studies have provided evidence that IL-15 administration serves an important role in tumor therapy (28,30). Zhang et al (31) found IL-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer, combination of mIL-15 with the anti-CD40 antibody enhanced the cytotoxic activity of NK cells and increased the total NK cell numbers. Yu et al (32) showed that IL-15 treatment resulted in a significant prolongation of survival in a metastatic murine colon carcinoma CT26 model. The data reported in their study showed enhancement of immune responses leading to increased antitumor activity.
Liver metastasis contributed to the major cause of mortality in patients with gastric cancer at advanced stages (3,6,33). To the best of our knowledge, this is the first study to demonstrate the role of IL-15 in LMGC. The present study has revealed that the presence of IL-15 could prolong the survival time of nude mice and prevent liver metastasis from gastric cancer. Furthermore, it was found that IL-15 enhances the cell activity of NK cells in nude mice or immunogenicity mice. Evidence exists that IL-15 serves a key role in murine NK cell homeostasis: NK cells are absent in IL-15 knockout (34) and IL-15Rα knockout mice (35). NK cells develop from CD34+ hematopoietic progenitors, first in the fetal liver, then in bone marrow and lymph nodes under the effect of the cytokine IL-15 (36). The liver may have unique precursors for memory NK cells, which are developmentally distinct from NK cells derived from bone marrow (37).
The present study showed that changes in the immune microenvironment of the liver can affect tumor metastasis and antitumor properties. The antitumor effects of IL-15 observed in the present study are likely underestimated, since the experimental systems used here excluded the effect of T cells. IL-15 is also important for NK cell activation as IFN-γ and Granzyme B expression in NK cells is induced by IL-15, and deficient in the absence of IL-15 (38,39). IL-15 activated NK cells through the IL-15/IL-15Rα complex trans-presentation (40). For the soil, the mechanism of liver metastasis from gastric cancer was investigated from the perspective of the target organ immune microenvironment. Target organ microenvironment, particularly the immune microenvironment, performs an important role in tumor metastasis (41,42). The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology (43,44). NK cells are critical innate effectors with direct killing and regulatory roles, shown to be important antitumor effectors, exhibiting direct cytotoxicity and more regulatory, cytokine-mediated effects (45). Presumably, at least some of the aforementioned mechanisms could be responsible for the development of cytotoxic effectors against tumor cells in mice treated with IL-15.
In conclusion, IL-15 was found to exhibit a significant therapeutic effect on liver metastasis from gastric cancer by enhancing NK cell activity in a murine model. The findings of the present study provide the scientific basis, and it is expected that administration of IL-15 for clinical treatment of patients with gastric cancer liver metastasis will be seen in the future.
Acknowledgements
Not applicable.
Funding
The present study was supported by the Natural Science Foundation of China (grant no. 81272726), the Specialized Research Fund for the Doctoral Program of Higher Education (grant no. 20110071120097) and the Shanghai Municipal Health Bureau Research Project (grant no. 20114174).
Availability of data and materials
All data that were generated or analyzed in this study are included in this manuscript.
Authors' contributions
WW, HH and JJ conceived and designed the study. FD, ZC and ZL conducted the experiments. XL and HC performed the statistical analysis. YZ interpreted the statistical analysis, and reviewed and approved the final version of the manuscript to be published. All authors read and approved the manuscript.
Ethics approval and consent to participate
These experiments were approved by the Shanghai Medical Experimental Animal Care Commission.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
Smith RA, Cokkinides V and Brawley OW: Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 62:129–142. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI | |
Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T and Makuuchi M: Surgical resection of liver metastases of gastric cancer: An analysis of a 17-year experience with 22 patients. Surgery. 133:507–511. 2003. View Article : Google Scholar : PubMed/NCBI | |
Okuyama K, Isono K, Juan IK, Onoda S, Ochiai T, Yamamoto Y, Koide Y and Satoh H: Evaluation of treatment for gastric cancer with liver metastasis. Cancer. 55:2498–2505. 1985. View Article : Google Scholar : PubMed/NCBI | |
D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M and Karpeh MS: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 240:808–816. 2004. View Article : Google Scholar : PubMed/NCBI | |
Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T and Sasako M: Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 95:534–539. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kakeji Y, Morita M and Maehara Y: Strategies for treating liver metastasis from gastric cancer. Surg Today. 40:287–294. 2010. View Article : Google Scholar : PubMed/NCBI | |
Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E and Waldmann TA: A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine activated killer cells. Proc Natl Acad Sci USA. 91:4935–4939. 1994. View Article : Google Scholar : PubMed/NCBI | |
Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 264:965–968. 1994. View Article : Google Scholar : PubMed/NCBI | |
Perera LP: Interleukin 15: Its role in inflammation and immunity. Arch Immunol Ther Exp (Warsz). 48:457–464. 2000.PubMed/NCBI | |
Di Sabatino A, Calarota SA, Vidali F, Macdonald TT and Corazza GR: Role of IL-15 in immune-mediated andinfectious diseases. Cytokine Growth Factor Rev. 22:19–33. 2011. View Article : Google Scholar : PubMed/NCBI | |
Armitage RJ, Macduff BM, Eisenman J, Paxton R and Grabstein KH: IL-15 has stimulatory activityfor the induction of B cell proliferation and differentiation. J Immunol. 154:483–490. 1995.PubMed/NCBI | |
Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H and Caligiuri MA: Apotential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 99:937–943. 1997. View Article : Google Scholar : PubMed/NCBI | |
Di Santo JP, Kuhn R and Muller W: Common cytokine receptor chain (c)-dependent cytokines: Understanding in vivo functions by gene targeting. Immunol Rev. 148:19–34. 1995. View Article : Google Scholar : PubMed/NCBI | |
Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D and Sugamura K: Cutting edge: The common -chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 167:1–5. 2001. View Article : Google Scholar : PubMed/NCBI | |
Davies E, Reid S, Medina MF, Lichty B and Ashkar AA: IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. J Leukoc Biol. 88:529–536. 2010. View Article : Google Scholar : PubMed/NCBI | |
Oh S, Berzofsky JA, Burke DS, Waldmann TA and Perera LP: Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA. 100:3392–3397. 2003. View Article : Google Scholar : PubMed/NCBI | |
Munger W, DeJoy SQ, Jeyaseelan R Sr, Torley LW, Grabstein KH, Eisenmann J, Paxton R, Cox T, Wick MM and Kerwar SS: Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2. Cell Immunol. 165:289–293. 1995. View Article : Google Scholar : PubMed/NCBI | |
Steel JC, Waldmann TA and Morris JC: Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 33:35–41. 2012. View Article : Google Scholar : PubMed/NCBI | |
Paget S: The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 8:98–101. 1889. | |
Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D and Anderson D: Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:2822–2830. 1994. View Article : Google Scholar : PubMed/NCBI | |
D¨obbeling U, Dummer R, Laine E, Potoczna N, Qin JZ and Burg G: Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 92:252–258. 1998.PubMed/NCBI | |
Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, et al: Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 19:496–510. 2008. View Article : Google Scholar : PubMed/NCBI | |
Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM and Rosenberg S: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 113:293–301. 2008. View Article : Google Scholar : PubMed/NCBI | |
Schwartz RN, Stover L and Dutcher J: Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 16 11 Suppl 13:S11–S20. 2002. | |
Sheng YQ, Cui LX, He W, Xue L and Ba DN: Antitumor effects of human IL-15 gene modified lung cancer cell line. Chin J Cancer Res. 9:240–244. 1997. View Article : Google Scholar | |
Xia H, Luo LM, Wen JX and Tong WC: Inhibitory effects of recombinant human endostatin on growth and metastasis of lung adenocarcinoma LA795 in mice. Ai Zheng. 21:1197–1202. 2002.(In Chinese). PubMed/NCBI | |
Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewicz A, Drela N, Jalili A, Kamiński R, Kozar K and Jakóbisiak M: Complete tumor regressions induced by vaccination with IL-12 gene-transduced tumor cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother. 53:363–372. 2004. View Article : Google Scholar : PubMed/NCBI | |
Sabbagh L, Snell LM and Watts TH: TNF family ligands define niches for T cell memory. Trends Immunol. 28:333–339. 2007. View Article : Google Scholar : PubMed/NCBI | |
Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ and Evans R: Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol. 161:6977–6984. 1998.PubMed/NCBI | |
Zhang M, Yao Z, Dubois S, Ju W, Müller JR and Waldmann TA: Waldmann: Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA. 106:7513–7518. 2009. View Article : Google Scholar : PubMed/NCBI | |
Yu P, Steel JC, Zhang M, Morris JC and Waldmann TA: Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res. 16:6019–6028. 2010. View Article : Google Scholar : PubMed/NCBI | |
Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H and Maeta H: Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 235:86–91. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, et al: Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 191:771–780. 2000. View Article : Google Scholar : PubMed/NCBI | |
Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S and Ma A: IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 9:669–676. 1998. View Article : Google Scholar : PubMed/NCBI | |
Becknell B and Caligiuri MA: Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 86:209–239. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jiang X, Chen Y, Peng H and Tian Z: Memory NK cells: Why do they reside in the liver? Cell Mol Immunol. 10:196–201. 2013. View Article : Google Scholar : PubMed/NCBI | |
Minagawa M, Watanabe H, Miyaji C, Tomiyama K, Shimura H, Ito A, Ito M, Domen J, Weissman IL and Kawai K: Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKTcells or intraepithelial lymphocytes, in IL-2/IL-15 receptor beta-chain-deficient mice. J Immunol. 169:4153–4160. 2002. View Article : Google Scholar : PubMed/NCBI | |
Koka R, Burkett P, Chien M, Chai S, Boone DL and Ma A: Cutting edge: Murine dendritic cells require IL-15Ralpha to prime NK cells. J Immunol. 173:3594–3598. 2004. View Article : Google Scholar : PubMed/NCBI | |
Castillo EF and Schluns KS: Regulating the Immune system via IL-15 Transpresentation. Cytokine. 59:479–490. 2012. View Article : Google Scholar : PubMed/NCBI | |
Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 10:99–111. 2006. View Article : Google Scholar : PubMed/NCBI | |
Muller AJ and Scherle PA: Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 6:613–625. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hammerstrom AE, Cauley DH, Atkinson BJ and Sharma P: Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy. 31:813–828. 2011. View Article : Google Scholar : PubMed/NCBI | |
Cheson BD and Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin 7S lymphoma. N Engl J Med. 359:613–626. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ljunggren HG and Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 7:329–339. 2007. View Article : Google Scholar : PubMed/NCBI |